Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism
NCT01673646Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Apr 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pasireotide LAR in acromegaly and pituitary gigantism (3 arms), sponsored by Novartis. Primary endpoint: Total-group Response Rate at Month 3. Started Oct 2012; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
acromegalypituitary gigantism
Beyond the preview
Go deeper on NCT01673646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01673646.